Jim Simons Onconova Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Onconova Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 218,094 shares of ONTX stock, worth $128,675. This represents 0.0% of its overall portfolio holdings.

Number of Shares

218,094

Previous 268,194 18.68%

Holding current value

$128,675

Previous $271,000 52.77%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$0.57 - $1.0 $28,556 - $50,100	-50,100 Reduced 18.68%	218,094 $128,000
Q1 2024 May 13, 2024	BUY	$0.67 - $1.01 $46,466 - $70,046	69,353 Added 34.88%	268,194 $271,000
Q4 2023 Feb 13, 2024	BUY	$0.62 - $0.79 $9,391 - $11,966	15,147 Added 8.25%	198,841 $148,000
Q3 2023 Nov 14, 2023	SELL	$0.71 - $1.15 $36,195 - $58,626	-50,980 Reduced 21.72%	183,694 $131,000
Q2 2023 Aug 11, 2023	BUY	$0.67 - $1.42 $60,219 - $127,629	89,880 Added 62.07%	234,674 $277,000
Q1 2023 May 12, 2023	SELL	$0.69 - $1.42 $15,767 - $32,449	-22,852 Reduced 13.63%	144,794 $106,000
Q4 2022 Feb 13, 2023	SELL	$0.63 - $0.97 $23,592 - $36,324	-37,448 Reduced 18.26%	167,646 $108,000
Q3 2022 Nov 14, 2022	SELL	$0.95 - $1.45 $121,817 - $185,932	-128,229 Reduced 38.47%	205,094 $181,000
Q2 2022 Aug 12, 2022	BUY	$1.04 - $1.9 $12,043 - $22,002	11,580 Added 3.6%	333,323 $440,000
Q1 2022 May 13, 2022	BUY	$1.46 - $2.82 $274,649 - $530,487	188,116 Added 140.78%	321,743 $592,000
Q4 2021 Feb 11, 2022	BUY	$2.49 - $3.73 $332,731 - $498,428	133,627 New	133,627 $341,000

Others Institutions Holding ONTX

# of Institutions

Shares Held

2.85M

Call Options Held

Put Options Held

View Full List

About Onconova Therapeutics, Inc.

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

More about ONTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account